VALNEVA SE EO -_15
Commented by Fabian Lorenz on April 30th, 2025 | 07:15 CEST
Buy BioNTech after the crash? Valneva with vaccine problems! Vidac Pharma shares show potential!
BioNTech shares crashed by around 10% on Friday. So far, they have not been able to recover. What caused the setback? Should investors seize the opportunity? Analysts believe the German biotech heavyweight is on track. The same applies to Vidac Pharma. The news flow is extremely positive, but the stock is not making any headway. Analysts believe that Vidac shares could multiply in value. If the biotech company continues to be successful, a takeover could follow. And what is going on at Valneva? The stock is on a rollercoaster ride. Could a vaccine become a problem?
Read
Commented by André Will-Laudien on April 1st, 2025 | 07:20 CEST
Was that the Trump crash? Nevertheless, steeply upwards with Evotec, Bayer, BioNTech, Defence Therapeutics, or Valneva?
Since November 2024, Donald Trump has driven the markets sharply upward - his controversial new presidency was largely celebrated by investors. Now, his leadership feels somewhat unsettling, with fires seemingly being set again at every corner. The new president is acting more imperiously than ever, with Panama, Canada, and Greenland verbally on the agenda as the next US states. Meanwhile, the US administration is facing a considerable deficit, which is to be addressed by drastically reducing the size of the public sector and introducing tariffs. Unsurprisingly, interest rates are now rising sharply, which is a reason for weaker prices in the biotech sector. However, the sector has done its homework and is emerging from a three-year downturn. Are we now at buying levels?
Read
Commented by Fabian Lorenz on February 10th, 2025 | 07:30 CET
BIOTECH stocks in RALLY MODE: Valneva, BioNxt Solutions, Evotec – BUY signal or correction?
After the 50% rally, the stock of BioNxt Solutions is currently consolidating. However, the next buy signal could be generated soon. There will likely be some exciting announcements this year and perhaps even a strategic partnership. The new R&D site in Munich will likely also attract attention for the innovative biotech company in Germany. After the catastrophic year, things have quieted down for the time being at Evotec. Or is it more that the air has been let out? After all, there is a lot of uncertainty about what skeletons might still be in the closet and how things should continue strategically. The stock market does not like that. In contrast, Valneva has had an impressive rally since mid-January. Last week, there was another big announcement. After 50%, is there more potential with the French company?
Read
Commented by Fabian Lorenz on February 4th, 2025 | 07:30 CET
OPPORTUNITIES in the Tariff Crash: TUI Facing a 50% Price Surge? Valneva Stock Strong! Multiplier with Desert Gold?
CAD 10 per ounce of gold. This is the current valuation of Desert Gold's resource - a real bargain with a gold price of over USD 2,800. There are good reasons why Desert Gold's share price should rise soon. Analysts even consider a multiplication of its value to be possible. Last week, Valneva showed just how quickly a stock can suddenly jump by 20% or more. Thanks to a multi-million dollar order from the US military, the downward trend in the share price has been broken. Are further price gains possible? Experts at TUI believe a 50% price jump is achievable. But is optimism ahead? Do these stocks offer opportunities in the tariff crash?
Read
Commented by André Will-Laudien on November 27th, 2024 | 07:00 CET
Biotech in focus! The 2025 blockbusters: Pfizer, BioNTech, Nyxoah, Valneva or Evotec - Who will take off?
The Q3 figures have now been processed. In the shadow of the tech giants on the Nasdaq, biotech stocks are currently being neglected. However, it is important to note that as pressure on the international economies increases, so does the likelihood of interest rate cuts by the central banks. Many investors have been underweight in biotech for quarters, prioritizing other sectors. All of this could be reversed in 2025. An early positioning with the most important protagonists seems promising. We are picking the best opportunities for you from the "Advent calendar."
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by André Will-Laudien on February 14th, 2023 | 15:54 CET
Election winners in the fight against cancer! Bayer, Defence Therapeutics, Formycon, Valneva - 300% rises are possible!
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make it much more likely that sufferers will survive. It is a matter of developing suitable active substances or launching modern therapies. Recently, mRNA technology has also been making a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. Which shares are currently in the spotlight?
Read
Commented by André Will-Laudien on January 3rd, 2023 | 07:26 CET
New COVID outbreak in China: BioNTech, Cardiol Therapeutics, CureVac and Valneva shares in focus again in 2023
The next COVID wave is rolling towards Europe. Representatives of the EU states therefore want to discuss a unified approach on Wednesday due to the latest development in China. The main issue is how to deal with entrants from China. A spokeswoman for the Federal Ministry of Health in Berlin said that the situation is being closely monitored and that the EU partners are also being consulted. At French airports, arrivals from China are already generally tested for the virus. Italy and Spain have also reacted with corresponding regulations. The German government sees no reason to do so so far. Is Germany too slow again, or is prudence the order of the day?
Read
Commented by Nico Popp on October 19th, 2022 | 13:52 CEST
Biotech funds looking over their shoulders: Bavarian Nordic, Cardiol Therapeutics, Valneva
A recent study by Accenture shows that consumers are not willing to reduce their spending on health and wellness - even if things are not going well economically. Despite uncertainties, respondents see spending in the areas of "health" and "fitness" as "essential." Those who pay for these areas are also likely to want to exhaust all options when it comes to health insurance benefits, such as medications and vaccines. Informed patients and consumers put pressure on their doctors when new therapies are available. Health insurers, who are also in competition with each other, are taking this into account. We highlight three biotech stocks and do the investment check.
Read